Immune effector cells and pancreatic beta cells

The interaction between immune effector cells and pancreatic beta cells is the central pathological axis of Type 1 Diabetes (T1D). In this autoimmune process, various immune cells, including CD8+ cytotoxic T cells and CD4+ helper T cells, infiltrate the pancreatic islets and selectively destroy the insulin-producing beta cells [1]. This destruction leads to a progressive loss of insulin secretion, resulting in hyperglycemia and the clinical onset of diabetes. Therapeutic interventions targeting this interface aim to arrest the autoimmune attack through immunomodulation or immunosuppression, thereby preserving the remaining beta cell mass [2]. Drugs like Teplizumab have been developed to delay the progression of T1D by targeting specific markers on immune cells to mitigate their effector functions against the pancreas [2]. Monitoring this interaction is typically done through C-peptide levels and the presence of islet-specific autoantibodies [1][3].

Other names

Beta cell-immune system interfaceIslet-infiltrating lymphocytes and pancreatic isletsInsulitis

Therapeutic strategies involve modulating immune effector cell activity (e.g., T-cell depletion or inhibition) to prevent the autoimmune destruction of pancreatic beta cells and preserve endogenous insulin production [1][2].